Skip to main content
MedPathMedPath Home
Clinical Trials/RPCEC00000355
RPCEC00000355
Not Yet Recruiting
N/A

Evaluation of biomarkers associated with clinical efficacy of CIMAvax-EGF® vaccine in patients with advanced stages (IIIB and IV) of non-small cell lung cancer who have been treated with this therapy. Physician Led - CIMAvax-EGF vaccine lung Biomarkers

Center of Molecular Immunology (CIM)0 sites140 target enrollmentMarch 11, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAdvanced non small cell lung cancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract Diseases

Overview

Phase
N/A
Intervention
Not specified
Conditions
Advanced non small cell lung cancer
Sponsor
Center of Molecular Immunology (CIM)
Enrollment
140
Status
Not Yet Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 11, 2021
End Date
June 12, 2024
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Center of Molecular Immunology (CIM)

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients of any sex and age greater than or equal to 18 years.
  • •2\. Patients who have signed the informed consent for the research.
  • •3\. Patients who meet the diagnostic criteria.
  • •4\. Patients with at least stable disease after 1st line chemotherapy, who have been included in clinical trials with the CIMAvax\-EGF vaccine or have been treated as part of routine medical practice.
  • •5\. Patients who have completed the induction stage with the CIMAvax\-EGF® vaccine and are receiving the vaccine as maintenance therapy.
  • •6\. Patients with clinical status criteria (ECOG) from 0 to 2

Exclusion Criteria

  • •1\. Patients of childbearing potential who are not using adequate contraception (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of males (vasectomy, use of condoms) while the treatment lasts
  • •2\. Pregnant, lactating or postpartum patients.
  • •3\. Patients with uncontrolled intercurrent illnesses including, but not limited to: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes mellitus, arterial hypertension and psychiatric illnesses that imply the incompetence of the subject.
  • •4\. Patients with brain metastases.
  • •5\. Patients with acute allergic states or history of severe allergic reactions.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
N/A
Investigation of clinical biomarkers reflecting the neurological basis of depressive symptoms and their usefulness in novel therapeutic techniquedepressive symptoms
JPRN-UMIN000026411Gunma University210
Active, Not Recruiting
Phase 1
Biomarkermoderate-to-severe psoriasisMedDRA version: 19.0 Level: PT Classification code 10037153 Term: Psoriasis System Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
EUCTR2015-002588-40-DEniversity Hospital Schleswig-Holstein40
Recruiting
N/A
Validation for clinical utility of biomarkers for the early diagnosis of breast cancer
KCT0005212Seoul National University Hospital496
Not Yet Recruiting
N/A
CIMAvax-EGF/Lung cancer/Biomarkers/Prospective CTAdvanced non small cell lung cancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract Diseases
RPCEC00000392Center of Molecular Immunology130
Not Yet Recruiting
N/A
CIMAvaxEGF in Non Small Cell Lung Cancer. Exploratory Study of Biomarkerson-Small Cell Lung Cancer (NSCLC)
RPCEC00000445Center of Molecular Immunology (CIM)20